BRAF and colorectal carcinoma: In stage IV CRC, BRAF mutation status did not show a significant effect on DFS (HR 1.180, 95% CI 0.290–4.870, P = 0.82) or OS (HR 2.660, 95% CI 0.950–7.450, P = 0.0548).